stoxline Quote Chart Rank Option Currency Glossary
  
CohBar, Inc. (CWBR)
0.78  0 (0%)    06-10 15:12
Open: 0.80015
High: 0.80015
Volume: 1,298
  
Pre. Close: 0.78
Low: 0.78
Market Cap: 2(M)
Technical analysis
2024-06-13 4:42:35 PM
Short term     
Mid term     
Targets 6-month :  1.16 1-year :  1.36
Resists First :  1 Second :  1.16
Pivot price 0.79
Supports First :  0.69 Second :  0.5
MAs MA(5) :  0.78 MA(20) :  0.82
MA(100) :  0.83 MA(250) :  1.61
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  56.4 D(3) :  56
RSI RSI(14): 47.2
52-week High :  3.58 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CWBR ] has closed above bottom band by 42.9%. Bollinger Bands are 13.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.8 - 0.81 0.81 - 0.81
Low: 0.77 - 0.77 0.77 - 0.78
Close: 0.77 - 0.78 0.78 - 0.79
Company Description

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Headline News

Tue, 23 May 2023
CohBar Almost Quadruples amid Morphogenesis Merger - TipRanks.com - TipRanks

Tue, 23 May 2023
Why Is CohBar (CWBR) Stock Up 130% Today? - InvestorPlace

Tue, 23 May 2023
CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates - Yahoo Finance

Mon, 26 Sep 2022
7 Nasdaq Stocks to Sell Before They Die - InvestorPlace

Tue, 10 Aug 2021
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH ... - GlobeNewswire

Fri, 23 Apr 2021
CohBar: A Promising Early Pureplay On Mitochondrial-Based Therapeutics (CWBR) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 2 (M)
Held by Insiders 15 (%)
Held by Institutions 6.2 (%)
Shares Short 15 (K)
Shares Short P.Month 29 (K)
Stock Financials
EPS -4.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.26
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -48.4 %
Return on Equity (ttm) -84 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.48
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.18
PEG Ratio 0
Price to Book value 0.23
Price to Sales 0
Price to Cash Flow -0.29
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android